Robert Bradway earned a degree in Biology from Amherst College and later earned an MBA from Harvard University. He joined Morgan Stanley in New York in 1985 as a health care industry investment banker. In 1990 Robert moved to London and served as head of the international health care investment banking activities of Morgan Stanley. He later was responsible for corporate finance management.
Robert was Managing Director for banking department and corporate finance Europe, for Morgan Stanley in London after which he left the company and joined Amgen in 2006. He came into Amgen as Vice President, Operations Strategy. Robert was then promoted and became Vice President and Chief Financial Officer on April 2007. He served in that capacity until May 2010 when he was appointed President and Chief Operating Officer.
Robert was appointed to the Amgen Board of Directors in 2011. He became Chief Executive Officer in May 2012 and Chairman in January 2013. Robert is a member of the Board of Directors of Norfolk Southern Corporation and serves on its Audit and Governance committees.
The company that Robert leads is one of the largest publicly traded in the world. It was founded in April 8, 1980, by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmannn and Joseph Rubinfeld. Amgen is based in Thousand Oaks, California.
The biotechnology medicines company discovers, develops, manufactures and markets medicines for grievous illnesses. Amgen focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
The company markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. Amgen’s products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor both of which selectively stimulate the production of neutrophils; Embrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body’s response to inflammatory diseases; and other products.
With a background in biology, Robert has a clear understanding of the complex and advanced work his company does and not merely relying on his management and financial knowhow.
No comments:
Post a Comment